MetaStat, Inc. (MTST-OTC) Executive Informational Overview 4-23-2014

448 views

Published on

Crystal Research Associates has released a new Executive Informational Overview (EIO) on MetaStat, Inc. (MTST-OTC). This comprehensive, 68-page document updates an earlier EIO published on MetaStat in January 2013. The Company has achieved several significant milestones over the past year and a half, which are each detailed in the new EIO along with current product development and market descriptions for MetaStat’s diagnostic and therapeutic programs.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
448
On SlideShare
0
From Embeds
0
Number of Embeds
118
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

MetaStat, Inc. (MTST-OTC) Executive Informational Overview 4-23-2014

  1. 1. . • An updated 68‐page  Executive Informational Overview® (EIO) written by Crystal Research Associates on  MetaStat, Inc. (MTST) is available at  www.crystalra.com. • Report covers a range of topics:  o Oncology markets o MTST’s diagnostic and therapeutic product  development: MetaSite Breast, MenaCalc, and  MenaBloc o MTST’s novel approach centering on the Mena  protein and its alternatively spliced isoforms o Competition o …and other key fundamentals Crystal Research Associates Presents:  New Independent Equity Research Published April 23, 2014
  2. 2. . • Crystal Research Associates’ Executive Informational Overview® (EIO)  presents a crystal clear, comprehensive report on a company in a manner  that is easily understood by the Wall Street financial community • Details a company’s product/technology/service offerings, market size(s),  key intellectual property, leadership, growth strategy, competition, risks,  financial statements, key events, and other fundamental information.  • Free of investment ratings, target prices, and forward‐looking financial  models • Complete risks and disclosures included in each EIO • Trademarked EIOs are exclusively written by experienced, award‐winning  analysts at Crystal Research Associates What is an EIO?
  3. 3. . Overview of MetaStat, Inc. (MTST) • A life sciences company commercializing a new approach to reliably determine a patient’s  individual risk of developing systemic metastatic cancer, and then to help reduce this risk  through active intervention of the metastatic process • Portfolio includes two diagnostic platforms targeting breast, prostate, lung, and colorectal  cancers, which could enter the market as early as 2015, as well as a therapeutic program: • MetaSite Breast is a clinical laboratory assay (or test) to predict the likelihood of an  early‐stage breast cancer patient’s tumor spreading to distant body parts • MenaCalc is a diagnostic technology platform for use in determining individual levels  of variants of the Mena protein (called “Mena isoforms”) in cancer tissue. Mena has at  least five isoforms, and measuring the relationship between these variants can help  create an individual metastatic profile as early on in disease progression as possible. • MenaBloc therapeutics may ultimately prevent metastasis among high‐risk patients  when administered as a maintenance therapy after surgery or in conjunction with  chemotherapy and other targeted therapies.
  4. 4. . MetaStat Product Roadmap: Commercialization  Path in 2015 and Beyond
  5. 5. . Technology Introduction • In most individuals, the Mena protein is only present in developing embryos where the protein supports  nervous system branching. Mena becomes scarce and undetectable in healthy adults.  • However, Mena also appears in cancer cells, where it supports cancer invasion and metastasis by enabling  cancer cells to invade surrounding tissues and migrate toward and penetrate blood vessels. The key discovery forming the foundation for MetaStat’s product candidates is that the Mena protein  isoforms (variants) are important regulators of the metastatic cascade.
  6. 6. . Target Indications for Improving Metastatic Risk Stratification • MetaSite Breast and MenaCalc Breast diagnostics could provide  metastatic risk coverage to the  entire breast cancer market • ~ 225,000 new Stage 0‐3  breast cancer diagnoses/yr • Prostate cancer could also  become a major market for  MetaStat • 93% of all prostate cancers  are in the local or regional  stages at diagnosis— representing over 220,000  people each year who  could benefit from an  improved measure of their  risk of developing  metastatic prostate cancer
  7. 7. . New Developments Described in Report • Initial sales and marketing plans for MetaSite Breast, which is anticipated to commence sales in  2015 • MetaStat’s December 2013 presentation of results from a large‐scale study of its MetaSite Breast  test at the San Antonio Breast Cancer Symposium • Results of a clinical validation of the MenaCalc technology presented at the 2014 Annual Meeting  of the U.S. and Canadian Academy of Pathology • The October 2013 opening of a drug discovery laboratory in affiliation with Stony Brook University • Recent license agreements with MIT and other institutions for the use of alternatively spliced  mRNA and protein isoform markers in the diagnosis, prognosis, and treatment of metastatic,  epithelial‐based solid tumors—which is central to the Company’s ongoing MenaBloc therapeutic  development • Additions to executive leadership that include a former senior executive from Roche as MetaStat’s  new Head of Diagnostics • Establishment of a highly skilled Scientific Advisory Board for Therapeutics • Current patent position and strategies • Most recent historical financial position and fundraising goals
  8. 8. . • Highly experienced—CEO and CMO Dr. Oscar L. Bronsther is a diplomat, American Board of  Surgery; chairman, Section of General Surgery, at Inova Fairfax Hospital; and clinical professor of  surgery at George Washington University in Washington, D.C. • MetaStat’s Head of Diagnostics Dr. Heiner Dreismann comes to the company from Roche, where  he was president and CEO of Roche Molecular Systems, head of global business development for  Roche Diagnostics, and member of Roche’s Global Diagnostic Executive Committee o Scientific Advisory Board for Therapeutics includes individuals from Duke University and the  Duke‐NUS Medical School, the Dana‐Farber Cancer Institute, the Cold Spring Harbor  Laboratory, and MIT o Scientific Advisory Board for Diagnostics includes individuals from the Department of  Anatomy and Structural Biology and the Department of Epidemiology and Population Health  at the Albert Einstein College of Medicine, and the Koch Institute for Integrative Cancer  Research at MIT o Clinical Advisory Board includes an attending pathologist at New York Presbyterian Hospital  and a professor of medicine and women’s health at the Albert Einstein College of Medicine • The Board of Directors has considerable business acumen, and includes the CEO of FluoroPharma Medical Inc., the president and CEO of Frontier Airlines, Inc., and the CEO and chairman of Echo  Therapeutics, Inc. Management
  9. 9. . To read the entire 68‐page EIO on  MetaStat, Inc.  (MTST)  or find information on other companies under  coverage, please visit www.crystalra.com.
  10. 10. . Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has provided institutional‐quality research on small‐ and mid‐cap companies for the past decade. We are led by veteran Wall Street sell‐side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street and for providing consistent award‐winning analyses and developing long‐term relationships on both the buy‐side and sell‐ side. He has been consistently ranked among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5‐Star ranked for top biotechnology stock performance by Starmine. About Us Corporate Headquarters: 880 Third Avenue, 6th Floor New York, NY 10022 Office: (212) 851‐6685 Fax: (609) 395‐9339 Satellite Office Location: 2500 Quantum Lakes Drive, Suite 203 Boynton Beach, FL 33426 Office: (561) 542‐6903 Fax: (561) 853‐2246 Jeffrey J. Kraws, Chief Executive Officer Karen B. Goldfarb President & COO
  11. 11. . FACEBOOK — https://www.facebook.com/CrystalResearchAssociates TWITTER — http://twitter.com/crystalresearch YOUTUBE — https://www.youtube.com/user/crystalrsch LINKEDIN — http://www.linkedin.com/company/crystal‐research‐associates  SLIDESHARE — http://www.slideshare.net/crystalresearchassociates Connect with Crystal Research Associates

×